Non-Small-Cell Lung Cancer
Conditions
Interventions
level0:Erlotinib 50mg(daily) level1:Erlotinib 100mg(daily) level2:Erlotinib 150mg(daily) level0-2:Carboplatin AUC=6,Day1/Pemetrexed 500mg/m2,Day1/Bevacizumab 15mg/kg,Day1
Sponsors
Kansai Medical University Hirakata Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically proven non-squamous non-small cell lung cancer 2) Non-small cell lung cancer with stage IIIB,stage IV (UICC-7) 3) EGFR mutation positive 4) chemo naïve 5) Age: 20- years old 6) ECOG PS 0-1 7) Adequate organ function
Exclusion criteria
Exclusion criteria: 1)Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 2)History of radiation therapy for chest 3)With hemosputum 4)With active bleeding 5)Symptomatic brain metastasis 6)With active infectious disease 7)History of serious disease condition 8)With massive pleural effusion or ascitis 9)History of active double cancer 10)need to operation 11) History of pregnancy or lactation 12)History of active psychological disease 13) History of drug allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Response Rate, Disease Control Rate, Overall Survival | — |
Countries
Japan
Contacts
Public ContactTakashi Yokoi
Kansai Medical University Hirakata Hospital Thoracic oncology
Outcome results
None listed